Efficacy and safety of autoprobiotic therapy in patients with type 2 diabetes mellitus

The original article presents the results of a study in which 12 patients with DM type 2 received 14-day therapy with an industrial probiotic (E. faecium L3 strains) or autoprobiotic (patient's own E. faecium). Therapy with the industrial probiotic and autoprobiotic had approximately the same effect on the severity of gastroenterological complaints and the quantitative/qualitative characteristics of the intestinal microbiota. In the group of E. faecium autostrain, there was a significant decrease of C-reactive protein.

1. Sanjay K. Diabesity. J Pak Med Assoc. 2013. N 63 (4). Р. 532.

2. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016. N 387 (10026). Р. 1377–1396.

3. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019. P. 157–107843.

4. Муромцева Г. А., Концевая А. В., Константинов В. В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014. N 6 (13). С. 4–11.

5. Дедов И. И., Мельниченко Г. А., Шестакова М. В. Национальные клинические рекомендации по лечению морбилного ожирения у взрослых. 3-й пересмотр (Лечение морбидного ожирения у взрослых). Ожирение и метаболизм. 2018. N 15. Р. 53–70.

6. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) 2019. Russian Journal of Cardiology. 2020. N 25 (4). Р. 1–3839. (In Russ.)

7. Courcoulas AP, Christian NJ, Belle SH, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013. N 310 (22). Р. 2416–2425.

8. Courcoulas AP, Christian NJ, Belle SH, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013, N 310 (22). Р. 2416–2425.

9. Brunkwall L, Orho-Melander M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia. 2017. N 60 (6). Р. 943–951.

10. Ley R. E., Turnbaugh P., Klein S., et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006. N 444. Р. 1022–3.

11. Turnbaugh P. J., Hamady M., Yatsunenko T., et al. A core gut microbiome in obese and lean twins. Nature. 2009. N 457. Р. 480–4.

12. Wu X. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010. N 61. Р. 69–78.

13. Egshatyan L., Kashtanova D., Popenko A., et al. Gut microbiota and diet in patients with different glucose tolerance. Endocr Connect. 2016. N 5 (1). Р. 1–9.

14. Yassour, M., Lim, M.Y., Yun, H.S. et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med. 2016. N 8 (1). Р. 17.

15. Dao MC, Everard A, Aron-Wisnewsky J, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016. N 65. Р. 426–436. DOI: 10.1136/gutjnl‑2014–308778.

16. Forslund, K., Hildebrand, F., Nielsen, T. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015. N 528. Р. 262–266.

17. Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2019. N 9 (3). e017995.

18. Соловьева О. И., Симаненков В. И., Суворов А. Н. и др. Использование пробиотиков и аутопробиотиков в лечении синдрома раздраженной толстой кишки. Экспериментальная и клиническая гастроэнтерология. 2017. № 143 (7). Р. 115–120.